#cmps hashtag - Bluesky

Psychedelic depression drug heads for FDA filing as PTSD study starts $150M financing and a $200M warrant exercise extended cash runway into 2028, with final 26-week COMP360 data expected in early Q3 2026.

1 week ago

#CMPS Compass Pathways Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Highlights

www.stocktitan.net/news/CMPS/compass-pathwa...

0 0 0 0

Compass Pathways Announces Exercise of $200 Million in Outstanding Warrants Compass Pathways (Nasdaq: CMPS) exercised 35,059,448 outstanding warrants on February 26, 2026, generating approximately $200 million in proceeds. The company issued 15,160,619 ADSs and, to certain institutional investors, pre-funded warrants to purchase up to 19,898,829 ADSs. Compass intends to use these proceeds, plus ~$141 million from a Feb 20, 2026 public offering and existing cash, to fund COMP005 and COMP006 Phase 3 trials, a Phase 2b/3 COMP360 PTSD trial, commercial readiness, and working capital; combined funds are expected to fund operations into 2028.

1 month ago

#CMPS Compass Pathways Announces Exercise of $200 Million in Outstanding Warrants

www.stocktitan.net/news/CMPS/compass-pathwa...

0 0 0 0

1 month ago

Looking for FREE stock market news?

Check out Alpha Coverage: wealthwisedca.substack.com/p/alpha-cove...

#ICLN #CMPS #ORA #GOOG #TSLA #UBER #EVGO #CRWD #CODA #QBTS #ACHR #JOBY #ADBE #MSFT #WDAY #PANW #NOW #AMD #AAPL #NFLX #INFY #ROK #IBIT #BTC #HOOD #RVI #AIQ #ANET #TSEM #CRDO #CLS #MDB #PLTR

0 0 0 0

1 month ago

Compass Pathways shares surged over 30% on Tuesday after the company announced positive results from COMP006, the second of two pivotal Phase 3 trials for its psilocybin-based therapy COMP360 in treatment-resistant depression.

#CMPS #CMPSStock #COMP360 #CompassPathways #Psychedelics

0 0 0 0

1 month ago

Compass Pathways shares surged over 30% on Tuesday after the company announced positive results from COMP006, the second of two pivotal Phase 3 trials for its psilocybin-based therapy COMP360 in treatment-resistant depression.

#CMPS #CMPSStock #COMP360 #CompassPathways #Psychedelics

0 0 0 0

Market Wire News

@marketwirenews.com

1 month ago

JUST IN: ( NASDAQ: #CMPS ) Why Did Compass Pathways Stock Rocket Higher Today?

0 0 0 0

2 months ago

Compass Pathways announced that the US FDA has accepted its Investigational New Drug application for COMP360, a psilocybin-based therapy for PTSD.

#CMPS #Psilocybin #PTSD #CMPSStock #CMPSNews #CompassPathways #CompassPathwaysStock #CompassPathwaysNews #ClinicalTrial #COMP360 #FDAApproval
$CMPS

0 0 0 0

Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD LONDON& NEW YORK---- Compass Pathways plc, a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration has accepted its Investigational New Drug application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD.

2 months ago

#CMPS #HTGC Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD

www.stocktitan.net/news/CMPS/compass-pathwa...

0 0 0 0

4 months ago

COMPASS PATHWAYS FAST-TRACKS COMP360 LAUNCH BY UP TO A YEAR

#CMPS #CMPSStock #CMPSNews #CMPSStockNews #CompassPathways #CompassPathwaysStock #CompassPathwaysNews #CompassPathwaysStockNews COMP360 #PsychedelicTherapy #MentalHealthInnovation #Biotech #Psilocybin

1 0 0 0

InsiderFinance

@insiderfinance.com

4 months ago

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#SXC, #GRMN, #ACI, #CMPS, #HSAI

#OptionFlow #OptionsTrading #Trading

1 0 0 0

Compass Pathways Announces Third Quarter 2025 Financial Results and Business Highlights Including Acceleration of Commercial Launch Plans by 9-12 Months Compass Pathways (Nasdaq: CMPS) reported Q3 2025 results and said it is accelerating commercialization plans for COMP360 in treatment‑resistant depression by 9–12 months after completing enrollment in the second Phase 3 trial (COMP006, n=585) and a positive Type B FDA meeting in Sept 2025 discussing NDA strategy and potential rolling submission.Key near‑term data milestones: 9‑week COMP006 (Part A) and 26‑week COMP005 (Part B) in Q1 2026, and 26‑week COMP006 (Part B) in early Q3 2026. Cash was $185.9M at Sept 30, 2025, and management expects cash to fund operations into 2027. Q3 net loss was $137.7M driven by a $101.3M non‑cash warrant fair‑value adjustment.

4 months ago

#CMPS Compass Pathways Announces Third Quarter 2025 Financial Results and Business Highlights Including Acceleration of Commercial Launch Plans by 9-12 Months

www.stocktitan.net/news/CMPS/compass-pathwa...

0 0 0 0

SpaceNews

@spacenews.com.web.brid.gy

5 months ago

Let’s not allow the ‘Golden Age’ of space exploration to turn into fool’s gold In recent years, a popular slogan in the space industry has been, “We are entering the Golden Age of space exploration.” Indeed, we have witnessed unprecedented advancements in launch vehicles, the initial development of private space stations, and all other forms of space-related capabilities. This vision was strengthened even more during the inaugural address earlier […] The post Let’s not allow the ‘Golden Age’ of space exploration to turn into fool’s gold appeared first on SpaceNews.

1 1 0 0

Compass Pathways to Announce Third Quarter Financial Results on November 4, 2025 Compass Pathways (Nasdaq: CMPS) will report its third quarter financial results for the period ended September 30, 2025 on November 4, 2025. Management will provide an update on recent developments and host a conference call on November 4, 2025 at 8:00 AM ET (1:00 PM UK). A live webcast will be available at the company events page and will be archived for 30 days.Investors can access the webcast at: https://events.q4inc.com/attendee/698442687.

5 months ago

#CMPS Compass Pathways to Announce Third Quarter Financial Results on November 4, 2025

www.stocktitan.net/news/CMPS/compass-pathwa...

0 0 0 0

Compass Pathways Announces Publication of Results from Phase 2 Study of COMP360 Psilocybin for Post-Traumatic Stress Disorder Compass Pathways (NASDAQ:CMPS) has published results from its Phase 2 study of COMP360 psilocybin for Post-Traumatic Stress Disorder (PTSD) in the Journal of Psychopharmacology. The study evaluated a single 25mg dose in 22 patients across sites in the U.S. and U.K.Key findings demonstrate that COMP360 was well-tolerated with no serious adverse events. The treatment showed significant efficacy with 81.8% response rate at week 4 and 77.3% at week 12. Patients experienced substantial symptom improvement, with a 29.9-point reduction in CAPS-5 scores at week 4 and 29.5-point reduction at week 12. Notably, remission rates were 63.6% at week 4 and 54.5% at week 12.

6 months ago

#CMPS Compass Pathways Announces Publication of Results from Phase 2 Study of COMP360 Psilocybin for Post-Traumatic Stress Disorder

www.stocktitan.net/news/CMPS/compass-pathwa...

0 0 0 0

Most Searched, Tuesday August 5, 2025 – Crystal Equity Research

7 months ago

Most searched small-cap stocks, Tue Aug 5th - #QUBT #RXRX #RCAT #STAA #AIS #NVTS #DNN #VLRS #ALIT #UAVS #TLRY #PSIX #SBET #OPEN #ONDS #NGD #ESPR #CTEV #CMPS #AEO - More: crystalequityresearch.com/most-searche... - #smallcap

0 0 0 0

Most Searched, Monday August 4, 2025 – Crystal Equity Research

7 months ago

Most searched small-cap stocks, Mon Aug 4th - #INMB #FFAI #SRPT #VERB #NVTS #ONDS #SNGX #DNN #PBM #AEO #TLRY #SFIX #SBET #PLUG #OPEN #COMM #CMPS #REPL #BLDE - More: crystalequityresearch.com/most-searche... - #smallcap

0 0 0 0

8 months ago

Compass Pathways shared updates on its clinical pipeline and regulatory progress, highlighting momentum around its lead candidate COMP360 for treatment-resistant depression (TRD).

#CMPS #CompassPathways #CMPSStock #CMPSNews #CMPSStockNews #CompassPathwaysStock #CompassPathwaysNews
$CMPS

0 0 0 0

@nasdaq.activitypub.awakari.com.ap.brid.gy

8 months ago

Psychedelic drug stocks surged after Bloomberg News reported AbbVie is in talks to acquire Gilgamesh Pharmaceuticals in a ~$1B deal.

#ATAI #CMPS #MNMD #ATAIStock #CMPSStock #MNMDStock #Psychedelic #PsychedelicDrugs #PsychedelicStocks #PsychedelicMedicines
$ATAI $CMPS $MNMD $ABBV

0 0 0 0

Nasdaq

8 months ago

Compass (CMPS) Q2 Loss Improves 27% | The Motley Fool

#CMPS #f46fb330-790b-4e44-acf7-ac1fe1d45091 #data-news

Origin | Interest | Match

0 0 0 0

Compass Pathways Announces Second Quarter 2025 Financial Results and Business Highlights Compass Pathways (NASDAQ:CMPS) reported Q2 2025 financial results and significant clinical progress. The company achieved a positive primary endpoint in its first COMP360 Phase 3 trial for Treatment-Resistant Depression (TRD), demonstrating clinically meaningful depression reduction at 6 weeks with high statistical significance. The second Phase 3 trial continues enrollment with 26-week data expected in H2 2026.Financial highlights include a cash position of $221.9 million as of June 30, 2025, providing runway into 2027. Q2 2025 net loss was $38.4 million ($0.41 per share). The company expects FY2025 net cash used in operating activities between $120-145 million.Research and development expenses increased to $30.3 million in Q2 2025, primarily due to advancing Phase 3 trials. The company is exploring options for potential accelerated COMP360 filing for TRD following positive trial results.

8 months ago

#CMPS Compass Pathways Announces Second Quarter 2025 Financial Results and Business Highlights

www.stocktitan.net/news/CMPS/compass-pathwa...

0 0 0 0

Mental Health Biotech Compass Pathways Sets Q2 Earnings Date: Key Updates Expected July 31 Mental health innovation leader CMPS to host Q2 earnings call on July 31 at 8AM ET. Access live webcast and latest financial developments. Get details.

8 months ago

#CMPS Compass Pathways to Announce Second Quarter Financial Results on July 31, 2025

www.stocktitan.net/news/CMPS/compass-pathwa...

0 0 0 0

9 months ago

Compass Pathways shares fell ~46% on Monday after releasing Phase 3 data for its psilocybin-based treatment (COMP360) targeting treatment-resistant depression, which met its primary endpoint but disappointed investors expecting stronger efficacy.

#CMPS #CMPSStock #CMPSNews #ATAI #MNMD #ATAIStock

0 0 0 0

Market Wire News

@marketwirenews.com

9 months ago

Just In: ( NASDAQ: #CMPS ) PRISM Mid-Day Movers: Psychedelic Milestone and Weight Loss Fallout Shake Indexes

0 0 0 0

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

9 months ago

Most searched small-cap stocks, Mon Jun 23rd - #APLD #ZETA #WULF #INDO #RIG #BTE #VLRS #JBLU #CMPS #SSRM #QUBT #MGNX #MAAS #LEU #INDP #IDR #HUT #EVH #IREN #RXRX - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

PRISM MarketView

@prismmarketview.bsky.social

9 months ago

PRISM Mid-Day Movers:
#COMPASSPathways ( #CMPS) dives 45%
#wearehims & Hers ( #HIMS) drops 30%
Other PRISM Mid-Day Movers:
• CorMedix Inc. ( #CRMD) up 17.85%
• #skyebioscience , Inc. ( #SKYE) up 28.66%
• Houston American Energy Corp. ( #HUSA) up 43.78%
prismmarketview.com/prism-mid-da...

0 0 0 0

Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression Compass Pathways (NASDAQ: CMPS) has announced positive Phase 3 trial results for COMP360, its synthetic psilocybin treatment for Treatment-Resistant Depression (TRD). The COMP005 trial, involving 258 participants across 32 US sites, achieved its primary endpoint with a statistically significant reduction in depression symptoms. A single 25mg dose of COMP360 showed a clinically meaningful difference of -3.6 points versus placebo on the MADRS scale (p

9 months ago

#CMPS Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression

www.stocktitan.net/news/CMPS/compass-pathwa...

0 0 0 0